Durvalumab: A Review in Extensive-Stage SCLC

21Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Durvalumab (IMFINZI®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). In the pivotal phase III CASPIAN trial in previously untreated adults with ES-SCLC, the addition of durvalumab to chemotherapy for up to 4 cycles followed by maintenance durvalumab was associated with a significantly longer overall survival and a favourable hazard ratio for progression-free survival compared with chemotherapy alone for up to 6 cycles. A higher proportion of patients in the durvalumab plus chemotherapy group had an objective response compared with the chemotherapy alone group. The efficacy of durvalumab was also sustained with longer follow-up. Durvalumab in combination with etoposide and either carboplatin or cisplatin had a manageable tolerability profile in patients with ES-SCLC. Given the available evidence, durvalumab in combination with etoposide and either carboplatin or cisplatin represents a valuable treatment option for the first-line treatment of patients with ES-SCLC, and is an accepted standard of care option in this setting.

Cited by Powered by Scopus

This article is free to access.

This article is free to access.

21Citations
82Readers

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Al-Salama, Z. T. (2021, November 1). Durvalumab: A Review in Extensive-Stage SCLC. Targeted Oncology. Adis. https://doi.org/10.1007/s11523-021-00843-0

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

69%

Researcher 4

25%

Professor / Associate Prof. 1

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 9

47%

Pharmacology, Toxicology and Pharmaceut... 4

21%

Biochemistry, Genetics and Molecular Bi... 4

21%

Agricultural and Biological Sciences 2

11%

Save time finding and organizing research with Mendeley

Sign up for free